Diminished Sphingolipid Metabolism, a Hallmark of Future Type 2 Diabetes Pathogenesis, Is Linked to Pancreatic β Cell Dysfunction

iScience

Brian J. Cox¹  Yousef Manialawy¹  Erica P. Gunderson²  Andreea Obersterescu²  Saifur R. Khan²  Michael B. Wheeler² 

[1] Advanced Diagnostics, Metabolism, Toronto General Research Institute, ON, Canada;Department of Physiology, University of Toronto, ON, Canada;

关键词: Pathophysiology;    Human Physiology;    Genomics;    Bioinformatics;    Systems Biology;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: Gestational diabetes mellitus (GDM) is the top risk factor for future type 2 diabetes (T2D) development. Ethnicity profoundly influences who will transition from GDM to T2D, with high risk observed in Hispanic women. To better understand this risk, a nested 1:1 pair-matched, Hispanic-specific, case-control design was applied to a prospective cohort with GDM history. Women who were non-diabetic 6–9 weeks postpartum (baseline) were monitored for the development of T2D. Metabolomics were performed on baseline plasma to identify metabolic pathways associated with T2D risk. Notably, diminished sphingolipid metabolism was highly associated with future T2D. Defects in sphingolipid metabolism were further implicated by integrating metabolomics and genome-wide association data, which identified two significantly enriched T2D-linked genes, CERS2 and CERS4. Follow-up experiments in mice and cells demonstrated that inhibiting sphingolipid metabolism impaired pancreatic β cell function. These data suggest early postpartum alterations in sphingolipid biosynthesis contribute to β cell dysfunction and T2D risk.

【 授权许可】

Unknown